Skip to main content
OpenTrials
Completed

NCT Number: NCT00530842

Effect of Tiotropium Plus Salmeterol vs. Fluticasone/Salmeterol on Static Lung Volumes and Exercise Endurance in COPD

The primary objective of this study is to demonstrate that treatment with a free combination of tiotropium and salmeterol provides superior improvement in static lung volumes and exercise tolerance compared to a fixed combination of fluticasone and salmeterol in patients with COPD.

The secondary objective includes assessment of safety.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Pulmonary Disease, Chronic Obstructive Chronic Disease Disease Attributes Lung Diseases Lung Diseases, Obstructive Pathologic Processes Pathological Conditions, Signs and Symptoms Respiratory Tract Diseases

Age range

40 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

205.334.4309 Boehringer Ingelheim Investigational Site, Gänserndorf, Austria

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • The patient has signed an Informed Consent Form in accordance with GCP and local legislative requirements prior to participation in the trial, i.e., prior to pre-trial washout of any restricted medications.
  • The patient has a clinical diagnosis of chronic obstructive pulmonary disease (COPD).
  • The patient has relatively stable, moderate to severe airway obstruction.
  • The patient has a pre-bronchodilator forced expiratory volume in the first second (FEV1) less than or equal to 65% of predicted normal determined at Visit 1 using the following predicted equations (R94-1408):
  • Males Forced expiratory volume in the first second (FEV1) predicted [Litres (L)] = 4.30 x Height [metres] minus 0.029 x Age [years] minus 2.49
  • Females Forced expiratory volume in the first second (FEV1) predicted [Litres (L)] = 3.95 x Height [metres] minus 0.025 x Age [years] minus 2.60 and a Thoracic Gas Volume (Functional residual volume) ((TGV)(FRC)) bigger than 120% predicted normal at visit 1 (or historical data not older than 6 month)
  • Males Thoracic Gas Volume (Functional residual volume) ((TGV(FRC)) pred. [Litres (L)] = 2.34 x Height [metres] + 0.009 x Age [years] minus 1.09
  • Females Thoracic Gas Volume (Functional residual volume) ((TGV(FRC)) pred. [Litres (L)] = 2.24 x Height [metres] + 0.001 x Age [years] minus 1.00
  • The patient is at least 40 years and less than or equal to 75 years old.
  • The patient has a cigarette smoking history of at least 10 pack-years. A pack-year is defined as the equivalent of smoking one pack of cigarettes per day for a year.
  • The patient is able to perform all specified procedures and able to maintain all necessary records during the study period as required in the protocol.
  • The patient is able to inhale the trial medication from the HandiHaler device.
  • The patient is able to inhale the trial medication from the Diskus/Accuhaler device.

Exclusion criteria

  • a significant disease other than chronic obstructive pulmonary disease (COPD). (review contraindications for exercise testing),
  • a recent history of myocardial infarction within one year.
  • a recent history of heart failure, pulmonary oedema, or patients with cardiac arrhythmia or any contraindication to exercise described in the CTProtocol within the last 3.
  • daytime supplemental oxygen.
  • a diagnosis of known active tuberculosis.
  • a history of cancer within the last 5 years.
  • a history of life-threatening pulmonary obstruction, or a history of cystic fibrosis or bronchiectasis.
  • thoracotomy with pulmonary resection.
  • an upper respiratory tract infection or an exacerbation of chronic obstructive pulmonary disease (COPD)
  • a known hypersensitivity to anticholinergic drug, ß-adrenergic or corticosteroids, lactose or any other component of the inhalation capsule delivery system.
  • a known symptomatic prostatic hypertrophy or bladder neck obstruction.
  • a known moderate or severe renal insufficiency.
  • a known narrow-angle glaucoma.
  • a known untreated hypokalemia.
  • a known untreated thyrotoxicosis.
  • a history of asthma, allergic rhinitis or atopy, or a total blood eosinophil count larger than 600/mm3.
  • treatment with cromolyn sodium or nedocromil sodium
  • treatment with antihistamines or antileukotrienes.
  • treatment with tiotropium for 1 month before Visit 1.
  • treatment with oral corticosteroid medication.
  • Pregnant or nursing women or women of childbearing potential not using a medically approved means of contraception
  • a history of or active alcohol or drug abuse.
  • an investigational drug within 1 month or 10 half lives
  • a limitation of exercise performance as a result of factors other than fatigue or exertional dyspnoea.
  • participation in a rehabilitation program for chronic obstructive pulmonary disease (COPD).
  • treatment with monoamine oxidase inhibitors inhibitors or tricyclic antidepressants.
  • participation in another study.
  • more than eight puffs of salbutamol/day during the run-in period

Treatment and study plan

Tiotropium plus Salmeterol

Drug

fluticasone/salmeterol

Drug

Primary outcomes

  1. Post-dose TGV(FRC) (After 8 Weeks)

    Time frame: 8 weeks

    Post-dose TGV(FRC) (Thoracic Gas Volume; co-primary endpoint) after 8 weeks

  2. Endurance Time (After 8 Weeks)

    Time frame: 8 weeks

    Endurance time to the point of symptom limitation after 8 weeks during a constant work rate exercise test at 75% Wcap (co-primary endpoint)

Secondary outcomes

  1. Post-dose TGV(FRC) (After 4 Weeks)

    Time frame: 4 weeks

    Post-dose TGV(FRC) (Thoracic Gas Volume) after 4 weeks

  2. Endurance Time (After 4 Weeks)

    Time frame: 4 weeks

    Endurance time to the point of symptom limitation after 4 weeks during a constant work rate exercise test at 75% Wcap (co-primary endpoint)

  3. Static Lung Volumes

    Time frame: 8 weeks

    Trough TGV(FRC) (Thoracic Gas Volume) after 8 weeks (measured by bodyphlethysmography)

  4. Static Lung Volumes

    Time frame: 4 weeks

    Trough TGV(FRC) (Thoracic Gas Volume) after 4 weeks (measured by bodyphlethysmography)

  5. Static Lung Volumes

    Time frame: 8 weeks

    Trough RV (Residual Volume) after 8 weeks (measured by bodyphlethysmography)

  6. Static Lung Volumes

    Time frame: 4 weeks

    Trough RV (Residual Volume) after 4 weeks (measured by bodyphlethysmography)

  7. Static Lung Volumes

    Time frame: 8 weeks

    Post-dose RV (Residual Volume) after 8 weeks (measured by bodyphlethysmography)

  8. Static Lung Volumes

    Time frame: 4 weeks

    Post-dose RV (Residual Volume) after 4 weeks (measured by bodyphlethysmography)

  9. Static Lung Volumes

    Time frame: 8 weeks

    Trough IC (Inspiratory Capacity) after 8 weeks (measured by bodyphlethysmography)

  10. Static Lung Volumes

    Time frame: 4 weeks

    Trough IC (Inspiratory Capacity) after 4 weeks (measured by bodyphlethysmography)

  11. Static Lung Volumes

    Time frame: 8 weeks

    Post-dose IC (Inspiratory Capacity) after 8 weeks (measured by bodyphlethysmography)

  12. Static Lung Volumes

    Time frame: 4 weeks

    Post-dose IC (Inspiratory Capacity) after 4 weeks (measured by bodyphlethysmography)

  13. Static Lung Volumes

    Time frame: 8 weeks

    Trough IRV (Inspiratory Reserve Volume) after 8 weeks (measured by bodyphlethysmography)

  14. Static Lung Volumes

    Time frame: 4 weeks

    Trough IRV (Inspiratory Reserve Volume) after 4 weeks (measured by bodyphlethysmography)

  15. Static Lung Volumes

    Time frame: 8 weeks

    Post-dose IRV (Inspiratory Reserve Volume) after 8 weeks (measured by bodyphlethysmography)

  16. Static Lung Volumes

    Time frame: 4 weeks

    Post-dose IRV (Inspiratory Reserve Volume) after 4 weeks (measured by bodyphlethysmography)

  17. Static Lung Volumes

    Time frame: 8 weeks

    Trough TLC (Total Lung Capacity) after 8 weeks (measured by bodyphlethysmography)

  18. Static Lung Volumes

    Time frame: 4 weeks

    Trough TLC (Total Lung Capacity) after 4 weeks (measured by bodyphlethysmography)

  19. Static Lung Volumes

    Time frame: 8 weeks

    Post-dose TLC (Total Lung Capacity) after 8 weeks (measured by bodyphlethysmography)

  20. Static Lung Volumes

    Time frame: 4 weeks

    Post-dose TLC (Total Lung Capacity) after 4 weeks (measured by bodyphlethysmography)

  21. Static Lung Volumes (Percent)

    Time frame: 8 weeks

    Trough RV/TLC (Residual Volume over Total Lung Capacity) after 8 weeks (measured by bodyphlethysmography)

  22. Static Lung Volumes (Percent)

    Time frame: 4 weeks

    Trough RV/TLC (Residual Volume over Total Lung Capacity) after 4 weeks (measured by bodyphlethysmography)

  23. Static Lung Volumes (Percent)

    Time frame: 8 weeks

    Post-dose RV/TLC (Residual Volume over Total Lung Capacity) after 8 weeks (measured by bodyphlethysmography)

  24. Static Lung Volumes (Percent)

    Time frame: 4 weeks

    Post-dose RV/TLC (Residual Volume over Total Lung Capacity) after 4 weeks (measured by bodyphlethysmography)

  25. Static Lung Volumes (Percent)

    Time frame: 8 weeks

    Trough TGV/TLC (Thoracic Gas Volume over Total Lung Capacity) after 8 weeks (measured by bodyphlethysmography)

  26. Static Lung Volumes (Percent)

    Time frame: 4 weeks

    Trough TGV/TLC (Thoracic Gas Volume over Total Lung Capacity) after 4 weeks (measured by bodyphlethysmography)

  27. Static Lung Volumes (Percent)

    Time frame: 8 weeks

    Post-dose TGV/TLC (Thoracic Gas Volume over Total Lung Capacity) after 8 weeks (measured by bodyphlethysmography)

  28. Static Lung Volumes (Percent)

    Time frame: 4 weeks

    Post-dose TGV/TLC (Thoracic Gas Volume over Total Lung Capacity) after 4 weeks (measured by bodyphlethysmography)

  29. Slow Vital Capacity (SVC)

    Time frame: 8 weeks

    Trough SVC (Slow Vital Capacity) after 8 weeks (measured by spirometry)

  30. Slow Vital Capacity (SVC)

    Time frame: 4 weeks

    Trough SVC (Slow Vital Capacity) after 4 weeks (measured by spirometry)

  31. Slow Vital Capacity (SVC)

    Time frame: 8 weeks

    Post-dose SVC (Slow Vital Capacity) after 8 weeks (measured by spirometry)

  32. Slow Vital Capacity (SVC)

    Time frame: 4 weeks

    Post-dose SVC (Slow Vital Capacity) after 4 weeks (measured by spirometry)

  33. Forced Expiratory Volume in 1 Second (FEV1)

    Time frame: 8 weeks

    Trough FEV1 (Forced Expiratory Volume in 1 second) after 8 weeks (measured by spirometry)

  34. Forced Expiratory Volume in 1 Second (FEV1)

    Time frame: 4 weeks

    Trough FEV1 (Forced Expiratory Volume in 1 second) after 4 weeks (measured by spirometry)

  35. Forced Expiratory Volume in 1 Second (FEV1)

    Time frame: 8 weeks

    Post-dose FEV1 (Forced Expiratory Volume in 1 second) after 8 weeks (measured by spirometry)

  36. Forced Expiratory Volume in 1 Second (FEV1)

    Time frame: 4 weeks

    Post-dose FEV1 (Forced Expiratory Volume in 1 second) after 4 weeks (measured by spirometry)

  37. Forced Expiratory Volume in 1 Second (FEV1)

    Time frame: 8 weeks

    Trough percent predicted FEV1 (Forced Expiratory Volume in 1 second) according to ECCS after 8 weeks (measured by spirometry)

  38. Forced Expiratory Volume in 1 Second (FEV1)

    Time frame: 4 weeks

    Trough percent predicted FEV1 (Forced Expiratory Volume in 1 second) according to ECCS after 4 weeks (measured by spirometry)

  39. Forced Expiratory Volume in 1 Second (FEV1)

    Time frame: 8 weeks

    Post-dose percent predicted FEV1 (Forced Expiratory Volume in 1 second) according to ECCS after 8 weeks (measured by spirometry)

  40. Forced Expiratory Volume in 1 Second (FEV1)

    Time frame: 4 weeks

    Post-dose percent predicted FEV1 (Forced Expiratory Volume in 1 second) according to ECCS after 4 weeks (measured by spirometry)

  41. Forced Vital Capacity (FVC)

    Time frame: 8 weeks

    Trough FVC (Forced Vital Capacity) after 8 weeks (measured by spirometry)

  42. Forced Vital Capacity (FVC)

    Time frame: 4 weeks

    Trough FVC (Forced Vital Capacity) after 4 weeks (measured by spirometry)

  43. Forced Vital Capacity (FVC)

    Time frame: 8 weeks

    Post-dose FVC (Forced Vital Capacity) after 8 weeks (measured by spirometry)

  44. Forced Vital Capacity (FVC)

    Time frame: 4 weeks

    Post-dose FVC (Forced Vital Capacity) after 4 weeks (measured by spirometry)

  45. FEV1 Over FVC (Percent)

    Time frame: 8 weeks

    Trough FEV1 (Forced Expiratory Volume in 1 second) over FVC (Forced Vital Capacity) after 8 weeks (measured by spirometry)

  46. FEV1 Over FVC (Percent)

    Time frame: 4 weeks

    Trough FEV1 (Forced Expiratory Volume in 1 second) over FVC (Forced Vital Capacity) after 4 weeks (measured by spirometry)

  47. FEV1 Over FVC (Percent)

    Time frame: 8 weeks

    Post-dose FEV1 (Forced Expiratory Volume in 1 second) over FVC (Forced Vital Capacity) after 8 weeks (measured by spirometry)

  48. FEV1 Over FVC (Percent)

    Time frame: 4 weeks

    Post-dose FEV1 (Forced Expiratory Volume in 1 second) over FVC (Forced Vital Capacity) after 4 weeks (measured by spirometry)

  49. Symptom Intensity During Exercise

    Time frame: 8 weeks

    Isotime Borg dyspnea scale after 8 weeks, Unit on a Scale (min. 0, max 10), 0 = no dyspnea, 10 = worst imaginable dyspnea

  50. Symptom Intensity During Exercise

    Time frame: 4 weeks

    Isotime Borg dyspnea scale after 4 weeks, Unit on a Scale (min. 0, max. 10), 0 = no dyspnea, 10 = worst imaginable dyspnea

  51. Symptom Intensity During Exercise

    Time frame: 8 weeks

    Isotime Borg leg discomfort scale after 8 weeks, Unit on a Scale (min. 0, max. 10), 0 = no leg dyscomfort, 10 = worst imaginable leg dyscomfort

  52. Symptom Intensity During Exercise

    Time frame: 4 weeks

    Isotime Borg leg discomfort scale after 4 weeks, Unit on a Scale (min. 0, max. 10), 0 = no leg dyscomfort, 10 = worst imaginable leg dyscomfort

  53. Dyspnea and Leg Discomfort

    Time frame: 8 weeks

    Peak Borg dyspnea scale after 8 weeks, Unit on a Scale (min. 0, max 10)

  54. Dyspnea and Leg Discomfort

    Time frame: 8 weeks

    Peak Borg leg discomfort scale after 8 weeks, Unit on a Scale (min. 0, max 10)

  55. Locus of Symptom Limitation at Peak Exercise During Exercise

    Time frame: baseline

    Reason for stopping exercise at baseline (leg discomfort, breathing discomfort, both or none)

  56. Locus of Symptom Limitation at Peak Exercise During Exercise

    Time frame: 4 weeks

    Reason for stopping exercise after 4 weeks (leg discomfort, breathing discomfort, both or none)

  57. Locus of Symptom Limitation at Peak Exercise During Exercise

    Time frame: 8 weeks

    Reason for stopping exercise after 8 weeks (leg discomfort, breathing discomfort, both or none)

Sponsors and collaborators

Lead sponsor

Boehringer Ingelheim

Industry

Registry information

Official study title

Effect of Inhalation of a Free Combination of Tiotropium Once Daily 18 Mcg and Salmeterol Twice Daily 50 Mcg Versus a Fixed Combination of Fluticasone and Salmeterol Twice Daily (500/50 Mcg) on Static Lung Volumes and Exercise Tolerance in COPD Patients (a Randomised, Double-blind, Double Dummy, 16 (2 x 8) Weeks, Crossover Study).

Important dates

Study start
2007
Primary completion
2009
First posted
Sep 18, 2007
Registry last updated
Dec 24, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.